- Diabetes technology will take center stage in 2025, with the introduction of continuous ketone monitoring, integrated biosensing to elevate personalized health insights, and additional AID/CGM choices with new product launches and partnerships.
- Expanded indications for current medications like Mounjaro and Zepbound are expected, along with advancements in the development of a new triple agonist and once-weekly insulins for people with type 2 diabetes.
- Type 1 diabetes research will continue to move toward a functional cure as Vertex enters pivotal trials for their stem cell-derived islet cell therapy.
Reading Time: 4 minutes
2025 is shaping up to be a blockbuster year in diabetes care! From smart MDI systems to medications that pull triple duty, the future is looking smarter—and less invasive.
Here are several key advancements we expect to see launched in 2025.
Abbott’s Novel Continuous Glucose-Ketone Monitoring System
A new CGM that measures both blood sugar and ketones is closer than ever. This is going to be a huge advancement because a continuous ketone monitor (CKM) will notify you of elevated ketones before an emergency situation like diabetic ketoacidosis occurs. A ketone monitor will also allow those with type 1 diabetes to take an SGLT inhibitor (like Jardiance, Farxiga, or Zynquista) safely, which could pave the way for FDA approval of these medications for use in type 1 diabetes.
Dexcom G7 15-Day Sensor
Dexcom already submitted an application to the FDA for a 15-day sensor for the G7 CGM, so we anticipate approval in 2025. Current wear time for the G7 is 10.5 days, so this would add five additional days of monitoring and would cut the number of sensors needed per month from three to two. Dexcom’s over-the-counter CGM Stelo (for people with type 2 diabetes not on insulin) was already cleared for a 15-day sensor, so we expect another positive vote from the FDA soon.
Medtronic Simplera CGM
Medtronic and Abbott are collaborating on an integrated CGM – Abbott will supply Medtronic with a CGM to work exclusively with Medtronic smart dosing devices and software across both AID and Smart MDI systems. This is going to be huge because the primary reason people didn’t want to use a Medtronic pump in the past was because they didn’t like the form factor of the sensor. Development is underway.
Eversense 365 + Pump Partner
The Eversense 365 implantable CGM was approved in 2024 with an iCGM designation, so it’s ready to connect with a pump partner to become part of an AID system. (We just need one pump company to swipe right!) Eversense is in talks with several pump companies already, and we do think a partnership will be announced in 2025. Once the Eversense 365 is part of an AID system, it will really open the doors for more people to benefit from its unique implantable design.
Tandem’s Tubeless Mobi Insulin Pump
Tandem’s Tubeless Mobi (informally referred to as Tobi) is essentially the same pump as Tandem’s Mobi, just with a different type of cartridge that doesn’t require tubing and goes straight in. The goal is to allow people to customize the way they wear their pump with each cartridge change, switching between tubed and tubeless wear configurations. This would be Tandem’s first tubeless pump.
Sequel twiist AID System to Launch in the First Half of 2025
Sequel’s twiist was FDA-approved in 2024 as the first AID system that directly measures the volume and flow of insulin delivery, enabling it to rapidly detect obstructions or occlusions. It uses the Tidepool Loop algorithm and has the capacity to work interchangeably with different iCGMs. The pump weighs less than 2oz, is water resistant, and holds 300 units of insulin, making it a great hybrid closed-loop option for anyone with diabetes. We expect it to be out by June.
Once-Weekly Insulin for Type 2 Diabetes
Once-weekly insulins have been in development in the U.S. for years, but they have yet to receive FDA clearance. Novo Nordisk completed studies for their once-weekly insulin icodec, and Lilly’s efsitora alfa is in phase 3 of clinical trials. Weekly basal insulin could mean a significantly reduced diabetes management burden for millions of people, and we expect one or both insulins to be approved for use in type 2 diabetes later this year.
Vertex Gets Closer to a Functional Cure for Type 1 Diabetes
Vertex Pharmaceuticals has been conducting a clinical trial to evaluate the safety and effectiveness of an investigational islet cell infusion called VX-880 in adults with type 1 diabetes who have a history of severe low blood sugar and impaired hypoglycemic awareness. In November they announced they are entering pivotal trials, which is big news because it’s the first time a scalable cure for certain people with type 1 diabetes is entering a phase 3 clinical trial. We don’t know how long the trial will last, but it’s an exciting move for 2025, and we will anxiously await the results.
Novel Triple Agonist Retatrutide from Lilly
Retatrutide is what’s called a triple agonist, which is the next iteration of diabetes obesity drugs. It works by activating three receptors: glucagon-like peptide-1 receptor (GLP-1), gastric inhibitory polypeptide receptor (GIP), and glucagon receptor agonist (GCGR), resulting in improvements in glucose as well as weight loss. Retatrutide is in phase 3 clinical trial for use in type 2 diabetes. Once the phase 3 trials are completed, they’ll present data to the FDA.
Mounjaro and Zepbound Heart Health Indication
We’re expecting several new indications for tirzepatide, which is the component in Mounjaro and Zepbound. We’re waiting for the FDA-required cardiovascular outcome trials that were applied to other medications introduced for the treatment of type 2 diabetes over the past ten years. Tirzepatide will also be looked at for congestive heart failure, obstructive sleep apnea, delaying the progression of kidney disease, and osteoarthritis in the knees. This is so important because Mounjaro is a dual agonist, and it will have the same benefits shown in Ozempic. That means we’ll have more medication choices that treat more health conditions, and it will increase availability and access for more people.
Dexcom and Oura Ring Offer New Biosensing Insights
Oura Ring is a smart ring that continually collects data on over 20 biometrics that impact wellbeing, such as sleep, stress, heart health, and activity data. Their new partnership with Dexcom will allow CGM users to track glucose levels and understand the impact of behaviors and biology on metabolic health. The first app integration is expected to launch in the first half of 2025.
Key Takeaways
This year is poised to not only introduce transformative technologies and treatments, but also improve accessibility, ease, and outcomes for millions of people with type 1 and type 2 diabetes. We’re particularly excited about how a continuous ketone monitor could potentially influence approval of adjunct medications (GLP-1 or SGLT inhibitors) for people with type 1 diabetes, but we will have to wait and see what the year brings!
I really like the Dexcom G7 sensor but just wish the adhesive patch that contacts the skin and the over patch was a little wider to stick and stay in place better if they are going to extend the sensor to a 15 day wear period.
You can always buy your own overpatch and put it over it. Personally I don’t need anything more than what I have because mine doesn’t fall off, but everyone is different and the overpatches are a good option!
I’m in Vancouver, BC – they fall off in the summer and stick like glue in the winter – hard to peel off. Hot showers spikes sugars while affecting the overlay patch.
Try the Skin Tac Wipes. They are amazing! Wipe your skin prior to insertion and it sticks for the entire duration. You can order them on Amazon.
The Cost of Everything Diabetes Type 1&2 is RIDICULOUSLY HIGH! I’m on a Medical Committee through Robert Kennedy, Jr that WILL GET THESE COSTS DOWN FOR ALL AMERICANS NOT BASED ON EXPENSIVE MEDICAL INSURANCE COSTS. WE SAID WE ARE NOT TO BE TAKEN ADVANTAGE OF AFTER JANUARY 20, 2025 AS DOCTORS,NURSES,HOSPITALS, INSURANCE COMPANY,MEDICAL EQUIPMENT COMPANIES WILL BE PUT OUT OF BUSINESS FOR GOOD!!TIME FOR NO MORE NONSENSE OR OUR EARLY DEATHS!
I must be unusual! I have trouble getting my sensor off and I don’t use the overpatch. It could be because I’m 76 and tend not to sweat!
Everyone’s different, but we’re sure you’re not alone in that! 🙂
I use the Medtronic sensor over the sensor and transmitter I got Dr an IV 3000 it’s a clear path cu that holds IVs in place. It does a great job with holding it down n place. That means that be the f help the you
Exciting to see these changes! Science moves forward!
Until Vertex encapsulates those islet cells (eliminating the need for immune suppressing drugs), I don’t think we should be calling this a “cure”. This is simply a new therapy for T1 diabetes.
When those islets can be permanently implanted and allowed to multiply on their own, then we can call it a cure.
I’m hoping that the BCG vaccine trials prove to be the answer we’ve all been looking for:
https://www.faustmanlab.org/current-research/#bcg
Hadn’t heard of this. Thanks for sharing!
Yes I tend to agree with you regarding therapies involving immune suppressing drugs, but that’s as close as we can get right now. I personally don’t have much faith in the BCG approach, but I hope I’m wrong.
It’s only a cure when big pharma or lobbiest in congress have no access to be able to suppress it or to keep making money off all diabetics back’s due to the high costs of either it or any diabetes supplies
Any comments regarding the newer “finger clip” blood non-invasive sugar monitors that require no stick.
Thank you.
Companies have come and gone for the past 20 years with non-invasive technology, and I don’t think we need it anymore because the CGMs go in so easily and are accurate. I think we’re past the period of when we would need it.
The (relatively minor) advancement that I’m looking forward to is the integration of Omnipod 5/Dexcom G7 with Apple IOS. This has been “coming soon” for a long time and I am growing weary of having to carry an extra device (PDM) with me all the time. Get on it, Insulet!!!
I couldn’t agree with you more! Just pretend you’re an executive and you’re so important, you need two phones. 🙂
I personally like having a separate controller, as a woman with a purse it’s not a big deal. Also I think I would have to charge my phone more, the controller needs a charge every day.
Thank you for this wonderful update. In the last two years I made a couple of changes to my T1D therapy. One was in regards to my Tandem x2 pump from the 90 degree cannula insertion sets to the 30 degree. That eliminated my occlusions. The other change was my CGM. I went from the G6 to the G7 but had multiple issues. Not sure why. Out of the 9 sensors approved by Medicare for my 3 month use, only 3 lasted the full 10 days. I switched to the Abbott Freestyle Libre 2 Plus which is compatible with my Tandem x2 pump. I’ve gotten a full 15 days out of each sensor which is super accurate and the adhesive is amazing. I don’t even need an Overpatch. I can’t wait for the Tandem x3 to get released in the US, as well as approval for the Libre 3 Plus. I’ve been a T1D for over four decades and finally life has gotten easier.
I’ve also had poor luck with the G7. I don’t think I have had one that lasted 10 days. I got a single shipment once upon a time but I do much better with the G6. And the 30 minute warm up is fake news as far as I am concerned because it’s not accurate for the first 12-18 hours.
It’s important to report your issues to Dexcom, because they are working on quality improvement.
Glad you found a combination that works for you. If you have not yet already, please report your issues to Dexcom, as they are always working on quality improvement.
I’m hoping for a non-invasive CGM watch from Samsung. I’ve been waiting for triple agonist retatrutide. I hope they make enough before they put it out.
I wouldn’t get too excited over the non-invasive glucose sensing because it’s a long way away, it’s not as accurate, and since we have really good CGMs now, I think it’s past the time that it would make a significant improvement. In terms of retatrutide, it’s definitely going to be coming out, and Lilly is doing major studies for efficacy and safety. In the meantime, Mounjaro and Zepbound are both really good options.
Living with Type 1 Diabetes for 37 years, I completely agree with Adam Levbarg above. We need a real CURE not a ‘kindof cure but you need to be on anti-rejection drugs’ type of solution. This isn’t a cure, it’s a further burden, unless of course prevention of hypoglycemia is a live-saving decision.
I wish Dexcom would figure out another way to insert the sensor. I have arthritis in my hands and it is difficult for me to test open the device and then push the button to insert the sensor.
Since it’s every 10 and a half days, perhaps you can get help from a family member, friend or a neighbor to put it on, but but if you can’t get someone to help and if it is a significant problem, you may want to get the implantable sensor made by Eversense that stays under your skin for 12 months.
That is so true. I am 84 and I also have terrible getting them open.
After a year on Dexcom 6 I transferred to Abbotfreestyle libre. I no longer need my wifes help every 10 days and place it on my arm by myself every 15 days. I love it. ❤
That’s great! It’s nice that we have several pump and CGM options, with more on the way.
Steve and TCYD team. Great work bring the diabetes community such great arry of topics and discussions. I have been following since the beginning and feel the content is excellent along with great presentations skills.
T1D for 52 years now and have been a true diabetes advocate in many areas. As I look for a functional cure, I have been working (volunteer) with the Diabetes Research Institute out of the Univ of Miami. They are doing great work in this area and have been involved with diabetes research for over 50 years. Their new work has provided many companies with their trial results. I would love to have a conversation with TCOYD and the world-renowned Dr Mattiahs von Herrath. He is a very respected and accomplished scientist/physician in the field of immunology and drug development for T1D and T2D. The organization recently made some management changes. Great new CEO Michael Burton and Marketing guru Michael Myers. Their website has great information on their work in Cell therapy, Immunology, prevention, and T2D. I feel it would be a great overview of new areas of function/biological cure
Thanks for all your hard work and dedication!!
Thank you Bob, we will share with Dr. Edelman and the team. 🙂
Bob…thank you so much for the comment. That is such a great T1D research center, and I know Mattiahs well. Really good guy. Will check out their website and perhaps share info.
I use the Tandem Mobi and Dexcom G7. I wish the glucose reading was on the mobi. My 8 month old iPhone that has all the information from both devices broke down last week. People who helped me were extremely supportive at apple, Dexcom, and Tandem. but quite honestly it was horrible. There should be a glucose reading that comes with the device.. Technology breaks down. I ended up going back to using my glucometer until my phone was up and running.
Writing a letter to the nice folks at Tandem would be a good idea.
Wondering with the new ADA guidelines recommending CGM for all with diabetes, both T1 and T2, do you predict insurance companies will cover more broadly? With the incredible success and promising new indications for incretins, as well as other drugs, and the successes of people with T2DM actually being able to discontinue insulin as a result, the requirements for insulin use or Level II or III hypoglycemia for coverage is seemingly antiquating fast. I have patients who no longer have coverage due to their successes. Even with Stelo and Rio being over the counter, the cost is still prohibitive to many of my patients given the cost of many of the other drugs eating away already at their retirement savings.
Also, is there any news that InPen and the Stelo/ Rio CGM’s will have Receivers/Readers? I have patients who do not have the Smart Phones necessary to use.
Finally, I have a patient who has been desperately waiting to get into the Vertex trials. He lives in Michigan. Will they expand the sites? and do you anticipate this happening within the next year?
I absolutely love your offerings and know that I find them very useful with my practice. My patients, and me!, are eternally grateful for All you do to make diabetes management attainable and not so foreboding! You ROCK!
Hi Mary,
Great questions! Taking them one by one…
1. I believe insurance companies are covering CGMs more and more, especially anyone with type 2 diabetes on even one injection of insulin per day. Once the insurance companies realize how much money it saves them (ER visits, hospitalizations, etc) they will give them out free!
2. Anyone on insulin needs hypoglycemia emergency kits like Gvoke or Baqsimi. The rate may go down with these incretin drugs, but that’s a good thing. The cost of medications and devices is outrageous and something has to happen!
3. Have not heard yet…the OTC CGMs don’t have readers to my knowledge. I would prefer to give a prescription for the Dexcom G7 or FreeStyle Libre 3…that way the patient has a reader if they want it, and the alerts and alarms (which can be turned off).
4. Regarding Vertex, we’ll reach out to our contact there and let you know.
Thank you for your kind words – really appreciate it!
Medicare info needed. Still trying to decide what to do for Medicare, whether I should stay with resig or sign up with Kaiser. For weeks I’ve been trying to find out the cost of my durable medical equipment i.e. diabetic supplies. They will just say I have to pay 20% of it, but will not give me an actual cost. I’ve talked to member assistance, Medicare, gone into the Terralinda facility to talk to them directly, and the Medicare specialist for kaiser has tried to find out for me. What are some costs other people with Kaiser on medicare are finding? Actual costs so I can make an INFORMED DECISION. I use the Tandem mobi and Dexcom G7. 20% doesnt’ tell me numbers.
Hi Pamela,
Hopefully others in the community will respond with their experiences, but if you haven’t yet tried a SHIP counselor, they may be able to help:
https://www.shiphelp.org/
Or you could try reaching out to the Diabetes Patient Advocacy Coalition info@diabetespac.org to see if they have resources that could offer assistance.
You may also want to try Integrated Diabetes Services to see if they have ideas as well:
https://integrateddiabetes.com/
Hope you are able to make some headway!
As a former community health nurse with extensive care coordination experience working with diabetes patients, I’m excited to see innovations in diabetes care advancing. However, I also hope that insurance coverage keeps pace to ensure these technologies are accessible to those who need them most. It’s a step forward only if it truly reaches the communities who will benefit the most.
Well said, Megan!